Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
vcel
14.7 mil revenues
$4 after hrs
News.........
RADA Electronic Industries Radar Selected by Lockheed Martin for Laser Weapon Research Projects
I can see how that would happen. I also bought big in those 4-5 days of rfmd (20k). Several times I almost pressed the sell button. They kept giving me new confidence with each earnings, and at the announced merger with tqnt I resisted. I watched as it doubled with the merger and said to myself this is at my ideal sell price (10). But no. Again I almost sold in the pullback from 14 to 11 thinking this is played out . Why I didn't I can't tell you. So after the rs I have 5k After earnings came out OK ($77 new price) but I realized that doesn't reflect the merger at all. So I held. Now I'm looking at 100 and shaking.
Good luck binks, heres one for you to look at (VCEL). Now I'll also sit on 20k there
you're correct, it is rocketing past 80..............
this is rocketing to 80
Why VCEL will double in 2015............
Seeking Alpha article today
Summary
Vericel's commercial business should generate close to $50 million in sales in 2015. Based on the current market cap, the shares are trading at only 1.5x forward revenues.
The company's ixCELL-DCM study recently completed enrollment and will offer data in the first quarter of 2016. We expect the shares will run-up ahead of the data later this year.
Management has laid out an aggressive yet astute strategy to drive Vericel to profitability in the coming years. We believe valuation is extremely attractive and upside is significant.
Earnings from Seeking Alpha
Mitek Systems (NASDAQ:MITK):
FQ1 EPS of $0.05 beats by $0.05.
Revenue of $5.39M (+20.9% Y/Y) beats by $0.13M
Shares +3.38% AH.
Now 4.25
Interesting news item today, how does this factor in for RADA.....
I24 NEWS
Berlin will contribute an estimated 115 million euros for four new corvette warships for the Israeli navy report the German newspaper Bild am Sonntag. According to leaked official memos, the deal, which was struck in November with the Jewish state, will cost a total of 1 billion euros.
The deal can be finalized by the end of this year and only needs final approval by the German parliament’s budget committee, government spokesman Steffen Seibert stated.
The ships, constructed by the German firm Thyssen Krupp are being built in the northern port city of Kiel according to Bild am Sonntag.
According to the leaked memos, the German Defense Ministry is required to earmark a certain amount for “defense systems for Israel,” with the goal of “securing the economic region in the Mediterranean Sea.”
In 2013 Israel purchased six Dolphin submarines from Germany using a steep discount, with the first three submarines being delivered as a gift.
Earlier this year Israel’s Defense Minister Moshe Ya’alon and Israel Defense Forces Chief of Staff Lt. Gen. Benny Gantz approved plans to purchase four large missile boats and recruit the sailors to operate them, in order to ensure the Israeli navy is able to patrol and protect the new gas fields
NEWS: Marketwatch
Leading MOD Selects RADA's Tactical Radars for Its National Alert System RADA's Tactical Radar Systems Provide Volume Surveillance and Detection of Multiple Threat Types, Including UAVs, Mortars, and Rockets NETANYA, Israel, Dec. 4, 2014 (GLOBE NEWSWIRE) -- RADA Electronic Industries Ltd. (Nasdaq:RADA) announces the selection of its MHR-based tactical radars by a leading MOD of for its national alert system. The radars will detect and alert from short-range threats such as mortars, rockets, UAVs and alike. Deliveries are expected to be completed during 2015. The MHR - an S-Band, Software-Defined, Pulse-Doppler, AESA radar - has sophisticated beam forming capabilities and advanced signal processing, provides multiple missions on each radar platform, and offers unprecedented performance-to-price ratio. It is compact and mobile, delivering ideal organic, tactical surveillance solutions for force and border protection applications such as C-UAS, C-RAM, GMTI, air surveillance, and more. According to Zvi Alon, RADA's CEO, "We are extremely proud with this competitive selection of our technology. This is a major award of a radar program for RADA, which joins other strategic awards for radar programs during 2014. We believe that additional leading countries and integrators will follow this selection."
I bought 20k of this at 4 ,I didnt sell at 6 I didnt sell at 2 .
The whole story is yet to be written. Holding here also.
June 24, 2014,...Morgan Stanley Weath Mgmt add NCR's Mobile Deposit w MiSnap
http://investor.ncr.com/phoenix.zhtml?c=83840&p=irol-newsArticle_Print&ID=1942087&highlight=
Aastrom Announces Initiation of Commercial Sales of Bone Marrow by Marrow Donation, LLC
ANN ARBOR, Mich., June 24, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the initiation of commercial sales of bone marrow by Marrow Donation, LLC, the company's wholly owned bone marrow collection center located in San Diego, CA.
Aastrom founded Marrow Donation to provide high-quality bone marrow for internal research and development purposes. The company previously announced plans to expand its efforts at Marrow Donation to target the growing market for bone marrow and bone marrow-derived cells for research and development purposes across the biopharmaceutical industry.
"The initiation of commercial supply of bone marrow from Marrow Donation is an important step in our plan to create value by strategically leveraging our existing assets," said Nick Colangelo, president and CEO at Aastrom. "Based on the increasing interest in using bone marrow-derived cells for research purposes, this represents a promising new business platform for Aastrom."
Aastrom CEO...."The acquisition of Sanofi's CTRM business is a transformative transaction that positions Aastrom as a fully-integrated global regenerative medicine company," said Nick Colangelo, president and chief executive officer of Aastrom. "The CTRM business brings us global manufacturing, marketing and sales capabilities that are structured to support the current portfolio of marketed products as well as our future product development plans. This transaction also provides us with a platform to generate operating income to support the development of our high-potential pipeline products and continued growth through additional strategic transactions."
.......when announced the aquisition Stock price 6.90
.......completion of aquisition, stock price 4.16, what am I missing for a 40% drop?
Dont tell me stocks aren't manipulated
Mitek Systems, Inc. ’s ( MITK ) share price has entered into oversold territory with an RSI value of 29.1. The Zacks Consensus Estimate for Mitek Systems for the full year period has improved 1 cent over the past two months to -26 cents per share. Currently, Mitek Systems has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get in on ( MITK ) after its recent drop.
Over 4 million shares traded in 4 one million shr trades the past two days after hours, all above 8.03. Someone really wants shares
Something going on behind the scene
RFMD Awarded $9.7M Air Force Contract to Produce Millimeter Wave GaN Integrated Circuits Company Transferring 0.14 Micron GaN Technology and Manufacturing on 6-Inch Wafers to Combine Technology and Cost Leadership
GREENSBORO, N.C., March 25, 2014 (GLOBE NEWSWIRE) --
RFMD (Nasdaq:RFMD), a global leader in the design and manufacture of high-performance radio frequency solutions, today announced it has signed a $9.7 million agreement with the Manufacturing and Industrial Technologies Directorate within the Air Force Research Laboratory (AFRL) to transfer and produce a 0.14 micron Gallium Nitride (GaN) monolithic microwave integrated circuit (MMIC) technology. The technology will be scaled to 6-inch diameter wafers using RFMD's industry-leading 6-inch GaN-on-Silicon Carbide (SiC) manufacturing line. "Through this Air Force contract we have the opportunity to establish the industry's first 6-inch millimeter wave GaN-on-SiC process technology, allowing RFMD to expand our technology capabilities beyond 100GHz," said Gorden Cook, general manager of RFMD Power Broadband. "We expect this new technology will not only enable a new class of affordable power MMICs for defense applications such as radar and military communications, but also commercial applications including cable TV networking, microwave backhaul and cellular infrastructure." According to industry analyst firm Strategy Analytics, the GaN microelectronics market is expected to more than triple to $334 million by 2017, representing a compound annual growth rate (CAGR) of 28%. This market growth is led by growth in both military (radar, electronic warfare, communications) and commercial (power management, cellular, CATV, land mobile radios) applications. "AFRL has a distinguished history of developing high performance technologies with an understanding of underlying physics that drive reliability," added Cook. "RFMD plans to leverage AFRL's experience to offer reliable, 0.14 micron gate GaN power technology for mass production in our US-based, open foundry." GaN technology supports broad frequency bandwidths and high breakdown voltages in a small area. RFMD's 6-inch GaN wafer offers 2.5-times more useable area over competing 4-inch GaN wafer platforms currently available, resulting in 2.5 times more RF power devices per wafer. Millimeter wave GaN enables the best trade-off between key performance parameters such as power gain, bandwidth and efficiency for applications in the range of DC to over 100GHz.
RFMD Earns Samsung's Quality Grand Award as Best Quality Supplier GUMI, South Korea and GREENSBORO, N.C., Feb. 10, 2014 (GLOBE NEWSWIRE) -- RFMD (Nasdaq:RFMD), a global leader in the design and manufacture of high-performance radio frequency solutions, today announced that Samsung has presented RFMD with its Quality Grand Award at a ceremony held last week at Samsung Electronics' smartphone manufacturing operations in Gumi, South Korea. The award recognizes RFMD's superior execution in product quality and customer satisfaction and was presented to RFMD on behalf of its Cellular Products Group (CPG) team. RFMD was selected as the best quality supplier among Samsung Mobile's approximately 450 global suppliers.
News 4pm
Control Solutions With New Impedance Tuners for Smartphones and Mobile Devices RFMD Expands Industry-Leading Portfolio of Antenna Control Solutions With New Impedance Tuners for Smartphones and Mobile Devices New RF1105 Offers Broad Antenna Impedance Tuning Range to Optimize Antenna Efficiency in Today's Complex LTE and HSPA+ Cellular Devices
GREENSBORO, N.C., Nov. 19, 2013 (GLOBE NEWSWIRE)
-- RFMD (Nasdaq:RFMD), a global leader in the design and manufacture of high-performance radio frequency solutions, today unveiled its first impedance tuner, the RF1105, further expanding the Company's industry-leading portfolio of antenna control solutions. RFMD's programmable RF1105 functions as a tuner sub-system across all LTE frequency bands up to 2.7GHz, providing antenna feed matching over a wide frequency range. This simplifies antenna design and enables smartphone and mobile device OEMs to optimize antenna power and sensitivity while also maximizing battery life. As frequency bands proliferate, cellular antennas are required to operate over wider bandwidths, greatly increasing the need for RFMD's impedance tuners. According to industry analyst firm Strategy Analytics, the proliferation of multi-band LTE devices is expected to drive phenomenal growth in shipments of antenna tuning components, reaching 1.8 billion units per year by 2018. Due to its unique topology, the RF1105 offers broad symmetric tuner gain and linear performance for optimal power transfer to the antenna, improving total system efficiency, even under the most adverse operating conditions in multi-band LTE and HSPA+ applications. "RFMD's impedance tuners greatly expand our industry-leading portfolio of antenna control solutions while also providing customers the programmability and efficiency needed to simplify and accelerate antenna design in their flagship smartphones and tablets," said Eric Creviston, president of RFMD's Cellular Products Group. "The RF1105 is capable of matching almost any antenna impedance, providing customers breakthrough flexibility. As a result, the RF1105 is already included on several leading mobile reference designs, and RFMD continues to enjoy excellent customer demand for our antenna control solutions." Like RFMD's antenna tuners, its impedance tuners improve RF system efficiency between the transceiver and the antenna element. While RFMD's antenna tuners optimize radiated efficiency by adjusting or tuning an antenna's resonant frequency, its impedance tuners optimize power transfer to the antenna. Both are part of RFMD's portfolio of antenna control solutions, which also includes high-performance routing switches that optimize antenna selection and control and enhance cellular data throughput rates. RFMD's impedance tuners provide a dynamic matching environment and can be programmed to offer optimal performance across multiple conditions and usage cases. With the RF1105, smartphone OEMs can design antennas for optimal radiated efficiency while also reducing the potential tradeoffs associated with fixed matching components. It is sampling now with lead customers, and volume production is expected to begin in the first quarter of 2014.
AH two 500 sales at $5.90 4:27pm.......
excellent earnings report
GLA
What are you talking about.........
ANN ARBOR, Mich., Oct. 31, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today reported that the company has regained compliance with the $1.00 minimum bid price requirement for continued listing under NASDAQ Listing Rule 5550(a)(2).
Read more: http://www.nasdaq.com/press-release/aastrom-biosciences-regains-compliance-with-nasdaq-minimum-bid-requirement-20131031-00822#ixzz2jmVilKzy
from Barrons Online a few mins ago.............
Revenue in the three months ended in September rose 48%, year over year to $310.7 million, yielding EPS of 12 cents.
Analysts had been modeling $308 million and 10 cents.
For the current quarter the company sees revenue in a range from flat to up 5% from last quarter. That equates to $311 million to $326 million in revenue.
Consensus is for $325 million. EPS is seen in a range of 13 cents to 14 cents, a penny better than the consensus of 13 cents.
RFMD(R) Unveils First 1.2 GHz Power Doubler Amplifier Supporting New DOCSIS 3.1 Cable Specification RFCM3316 Combines Compact Size With Decreased Current Consumption, Allowing CATV Operators and MSOs an Easy Upgrade Path to Meet New DOCSIS 3.1 Requirements
GREENSBORO, N.C., Oct. 18, 2013 (GLOBE NEWSWIRE) -- RFMD (Nasdaq:RFMD), a global leader in the design and manufacture of high-performance radio frequency solutions, today unveiled its first power doubler amplifier in a multi-chip module to support the requirements of the new data over cable service interface specification (DOCSIS) 3.1. RFMD's new Gallium Nitride- (GaN-) based RFCM3316 allows cable operators and MSOs to easily upgrade existing CATV infrastructure to meet the power amplifier requirements of the new DOCSIS 3.1 standard, increasing effective downstream data rates from 160 Megabits per second (Mb/s) to 10 Gigabits per second (Gbit/s), and upstream data rates from 120 Mb/s to 1 Gbit/s when compared to DOCSIS 3.0. Due to the high output and gain benefits derived from RFMD's GaN-based RFCM3316, cable operators can upgrade their existing equipment within current locations, saving on both installation time and cost.
GREENSBORO, N.C., Oct. 8, 2013 (GLOBE NEWSWIRE) -- RFMD (RFMD), a global leader in the design and manufacture of high-performance radio frequency solutions, today announced that it has commenced high-volume production of multiple new power amplifiers (PAs) and power management integrated circuits (ICs) that incorporate RFMD's envelope tracking (ET) technology. RFMD's unique ET technology significantly enhances power efficiency in new LTE platforms, resulting in enhanced battery life across all modes and bands, increased network coverage, and higher data rate throughput.
RFMD is a pioneer in the development of RF power management and envelope tracking technology. Unlike traditional PAs that operate with a constant supply voltage, the supply voltage applied to RFMD's ET-enabled PAs is continuously adjusted so that the amplifier operates at maximum power efficiency. The result is much lower battery power consumption, particularly in LTE platforms.
RFMD's expanding ET product portfolio is tailored for today's leading LTE chipsets and provides full ET compatible coverage of all FD-LTE and TD-LTE bands (1-14, 17-21, 25-28, 38, 40, 41, and 44). RFMD's expanding portfolio of envelope tracking-enabled solutions includes its RF7389 and RF8085 multimode, multi-band PAs, the RF80xx(i) family of 10 single-band satellite PAs, and its RF8081 ET power management IC.
"This volume ramp-up of a broad family of envelope tracking-enabled products puts RFMD at the forefront of the ET revolution and is a testament to the market success of our technology, which is very well suited for the power demands of new LTE platforms now being rolled out across the globe," said Eric Creviston, president of RFMD's Cellular Products Group. "RFMD is very well positioned with power management technologies such as envelope tracking and average power tracking to expand our RF content in the newest generation of smartphones, tablets, ultrabooks and machine-to-machine (M2M) applications."
Mitek and Experian(R) Collaborate to Help Organizations Monetize the Mobile Channel -- Mitek's Mobile Photo Account Opening(TM) eliminates the notoriously cumbersome and error prone manual data entry on a mobile device by using the camera as the keyboard -- Experian's Precise ID gives clients the most complete and accurate view of a consumer's identity so they can make the right decisions -- Combined solution streamlines account opening by making it easy and safe for consumers to engage with organizations in the extremely popular mobile channel
SAN DIEGO and LAS VEGAS, Oct. 7, 2013 (GLOBE NEWSWIRE) -- Mitek (Nasdaq:MITK) (www.miteksystems.com), the leading innovator of mobile imaging for financial transactions, announced today at Money 2020 that it is working in partnership with Experian, the leading global information services company, to offer frictionless and safe mobile account opening. The marriage of Mitek's Mobile Photo Account Opening(TM) solution and Experian's fraud prevention and authentication services will help organizations streamline the account opening process giving them the ability to take a giant leap toward monetizing the mobile channel. Mitek's award winning Mobile Photo Account Opening reduces the friction in the account opening process by eliminating the notoriously cumbersome and error prone manual data entry on a mobile device. Consumers simply capture pictures of the front and the back of their driver's license and the validated data is automatically populated into the account opening application. Mobile Photo Account Opening seamlessly integrates with Experian's fraud detection and prevention platform which offers cutting-edge resources that enable Experian clients to outpace criminals by detecting, avoiding, and managing fraud activity -- all while helping clients meet mandated government and industry regulations such as the USA PATRIOT Act, the FACTA Red Flags Rule, and E-Signature requirements.
excerpt from Seeking alpha website ........
RF Micro Devices (RFMD), is ready for a return to market dominance and as a result should see an increase in its stock price taking it to multi-year highs. Yesterday, there were two pivotal announcements that support my belief in RFMD's forward progress toward becoming the dominant RF systems player in the mobile sector. 1) RFMD announced it is expanding capacity due to increased product demand from one of its key customers. 2) Apple (AAPL) announced it had sold out its new iPhones in under two days; this beat some analysts' forecasts by almost double (9 million vs. 5 million). In trading, we saw RFMD break out to a two and a half year high on over three times normal volume.
RF Micro Devices Inc is a leading designer and manufacturer of high-performance radio frequency solutions in mobile device, wireless infrastructure, Wi-Fi, cable/broadband, and the aerospace and defense markets.
RFMD(R) Expands Assembly Capacity to Accommodate Strong Product Demand
Expansion Boosts Internal Assembly, Will Include Advanced Flip Chip Capabilities
GREENSBORO, N.C., Sept. 23, 2013 (GLOBE NEWSWIRE) -- RFMD (RFMD), a global leader in the design and manufacture of high-performance radio frequency solutions, today announced it has successfully completed a recently announced expansion of its test, tape and reel, and assembly facility, located in Beijing, China. In addition to newly qualified internal assembly capacity for power amplifiers (PAs), switch-based products, and antenna control solutions, RFMD is also qualifying advanced flip chip capabilities for its 2G, 3G, and 4G LTE and TD-LTE products.
RFMD anticipates the expansion will enable it to quickly accelerate internal assembly to accommodate broad customer demand for its expanding portfolio of RF solutions. The capacity expansion efforts and resulting increase in internal assembly are expected to contribute to RFMD's stated goal of expanding non-GAAP gross margin by 300-400 bps by the March 2014 quarter, as compared to non-GAAP gross margin of 34.4% achieved in the March 2013 quarter. On August 26, 2013, RFMD announced it was on track to achieve another major gross margin expansion initiative -- the ramp of its new low-cost CMOS PA for entry market 2G handsets.
RFMD's high-performance RF solutions are broadly adopted across multiple growth markets and applications, including smartphones, handsets, tablets, notebooks, Wi-Fi, CATV, and hi-rel applications. The increasing use of RF technology is core to the collective value of wireless connections between people, data, processes, and objects, and is central to the popular concept of the Internet of Things. According to Cisco, the Internet of Things is expected to grow at a compound annual growth rate of 25% during 2012 to 2020, reaching approximately 50 billion connected devices by 2020.
RFMD(R) Introduces World's First 6-Inch GaN-on-SiC Wafers for RF Power
Transistors
Company Converting All Gallium Nitride (GaN) Processes to High-Volume 6-Inch
Wafer Fabrication to Reduce Platform Cost, Address Growth Opportunities
GREENSBORO, N.C., Sept. 19, 2013 (GLOBE NEWSWIRE) -- RFMD (Nasdaq:RFMD), a
global leader in the design and manufacture of high-performance radio frequency
solutions, today introduced the world's first 6-inch GaN-on-Silicon Carbide
(SiC) wafers for manufacturing RF power transistors for both military and
commercial use. The company is converting all GaN production and development to
6-inch diameter wafers using its existing high-volume, 6-inch GaAs foundry to
reduce platform cost for the growing GaN device market.
"We are pleased to introduce the industry's first 6-inch GaN-on-SiC RF
technology on RFMD's existing high- volume 6-inch GaAs manufacturing line,"
said Bob Bruggeworth, president and CEO of RFMD. "This merging of production of
GaN and GaAs is part of our 'GaN-in-GaAs Fab' strategy to repurpose existing
fab capacity to better address growth opportunities from innovative new
GaN-based products."
According to industry analyst firm Strategy Analytics, the GaN
microelectronics market is expected to more than triple to $334 million by
2017, representing a compound annual growth rate (CAGR) of 28%. This market
growth is led by growth in both military (radar, electronic warfare,
communications) and commercial (power management, cellular, CATV, land mobile
radios) applications.
"By leveraging our technology leadership and high-volume expertise in 6-inch
GaAs production, RFMD will now be able to add 6-inch GaN capabilities to
deliver new RF Power products that we expect will accelerate revenue growth in
our communications, CATV, power conversion, radar, jamming, aerospace and open
foundry businesses," said Dr. Jeff Shealy, vice-president of RFMD Power
Broadband.
GaN technology supports broad frequency bandwidths and high breakdown
voltages in a small area. A 6-inch GaN wafer offers 2.5-times more useable area
over competing 4-inch GaN wafer platforms currently available, resulting in 2.5
times more RF power devices per wafer. Larger area-per-wafer and subsequent
lower cost per unit area (in dollars per square millimeter) is key to enabling
affordable, high performance power monolithic microwave ICs (MMICs) for
military and commercial applications. RFMD expects to complete qualification of
its 6-inch GaN platforms in 2014.
Breakthrough CMOS Power Amplifiers
RFMD(R) Surpasses Shipment Milestone With Breakthrough CMOS Power Amplifiers
GREENSBORO, N.C., Aug. 26, 2013 (GLOBE NEWSWIRE) -- RFMD (Nasdaq:RFMD), a
global leader in the design and manufacture of high-performance radio frequency
solutions, today announced it has shipped more than one million RF7196D
high-power, high-efficiency CMOS power amplifiers (PAs). The ultra-low cost
RF7196D is RFMD's newest and most innovative CMOS PA, delivering a
revolutionary combination of cost, size and performance. It is in mass
production in support of multiple high-volume 2G and 3G handset platforms, and
shipments are expected to increase rapidly, reaching approximately 10 million
units by the end of the September quarter.
RFMD is seeing strong adoption of its CMOS power amplifier technologies in
next-generation handset platforms targeting emerging markets. The Company is
migrating its diverse set of customers of 2G power amplifiers (both GaAs and
CMOS) to its ultra-low cost RF7196D and expects shipments will more than double
in the December quarter and exceed 100 million units worldwide in calendar
2014.
Trade Halted 9:25 am News Pending...........I'm looking for big news here
GLA
Astm beats earnings estimate by .03
Mitek Receives 16th Patent -- Mobile Balance Transfer Process San Diego County Credit Union Using Balance Transfer Solution to Provide Better Banking Experience to Customers and Acquire New Credit Card Balances
SAN DIEGO, July 9, 2013 (GLOBE NEWSWIRE) -- Mitek (Nasdaq:MITK) (www.miteksystems.com), a leading mobile imaging software solutions provider, today announced that it has been issued U.S. Patent No. 8,483,473, "SYSTEMS AND METHODS FOR OBTAINING FINANCIAL OFFERS USING MOBILE IMAGE CAPTURE," by the U.S. Patent and Trademark Office. This, the company's 16th patent, describes the process of capturing an image of a credit card statement and being presented with organized, targeted offers to transfer the balance. The Mobile Balance Transfer(TM) solution is currently in use at San Diego County Credit Union and under consideration at numerous other institutions. Consumers want a simple, mobile-friendly process to shop for a better credit card rate and financial institutions need a new, cost effective means to acquire new credit card customers or increase average balances for existing customers leveraging the popular mobile channel. Mitek's Mobile Balance Transfer solution achieves both of these goals. The consumer simply snaps a photo of their current credit card statement coupon. Then, within seconds, the Mitek imaging system processes the request and validates the data, allowing the organization to quickly present options for transferring the existing balance. Consumers in turn get a lower credit card rate and easily transfer their existing balance to the new issuer and financial institutions increase profitability by obtaining new credit card customers and higher balances from existing customers. "Mitek's Mobile Balance Transfer solution makes it possible for San Diego County Credit Union customers to use their mobile phones to transfer their credit card accounts from other financial institutions to an attractive, low-rate SDCCU Visa credit card," said San Diego County Credit Union President & CEO, Teresa Halleck. "This new app is just another way SDCCU is providing a better banking experience to our customers on the go."
My best advice...........
....after some research, look up your favorite stock on the motley FOOL site and do exactly the opposite of their recommendations.
In April this year they scathed RAD, ("no way to sustain profitability") I bought 20k at $1.75 . The have maintained that stance right up to today.
This has worked several times for me, I dont even know whether they are corrupt, clever manipulators or just FOOLS.
Everyone has a strategy. I'm waiting for their take on MITEK (MITK)
Good Luck all.
From Motley FOOL........... (aptly named)
As compared to other pharm stocks, CVS and WAG
"Rite Aid, though, has been the laggard of these three, and the introduction of generics has not helped as much as it should have."
Truth............If you invested 10,000 in each of these three companies exactly two months ago you would now have , in your pocket,...
CVS $57.76 >>> $58.76 173 shares for 10k dollars = $173 return today
WAG $48.67 >>> $49.67 205 shares for 10k dollars = $205 return today
RAD $1.78 >>> $3.11 5618 shares for 10k dollars = $7472 return today
Congrats to the "laggard" company investors
RFMD raised to STRONG BUY by Charter this am.............
Basics of Fin results today pm
Total revenue for the second quarter of fiscal 2013 was $3.2 million compared to total revenue of $1.2 million in the second quarter of fiscal 2012, driven primarily by growth in software license revenue.
GAAP net loss for the second quarter of fiscal 2013 was $2.4 million, or $0.09 per share, compared to GAAP net loss of $2.8 million, or $0.11 on a per share basis, in the second quarter of fiscal 2012. Non-GAAP net loss for the second quarter of fiscal 2013 was $1.7 million, or $0.06 per share, compared to non-GAAP net loss of $2.2 million, or $0.09 per diluted share, in the second quarter of fiscal 2012.
Healthcare Conference
ARIAD To Present at The RBC Capital Markets Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--February 19, 2013--
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
present at the RBC Capital Markets Healthcare Conference being held in New York
City. Harvey J. Berger, M.D., chairman and chief executive officer, will
provide an overview of the Company's business on Tuesday, February 26, at 9:00
a.m. (ET).
The ARIAD presentation at the RBC Capital Markets Healthcare Conference will
be webcast live and can be accessed by visiting the investor relations section
of the Company's website at http://www.ariad.com/investor. A replay of the
presentation will also be available and archived on the site for three weeks.
Alexandria Real Estate Equities, Inc. Announces 15-Year Lease with ARIAD
Pharmaceuticals, Inc. for its Corporate and R&D Headquarters at the Alexandria
Center(TM) at Kendall Square
PASADENA, Calif., Jan. 7, 2013 /PRNewswire via COMTEX/ -- Alexandria Real Estate
Equities, Inc. (ARE), the leading owner, operator, and developer of high-quality,
sustainable real estate for the broad and diverse life science industry, is
pleased to announce that ARIAD Pharmaceuticals, Inc., a leading, fully integrated
oncology company, will establish its state-of-the-art corporate and research and
development headquarters at the Alexandria Center(TM) at Kendall Square in
Cambridge, Massachusetts. ARIAD has executed a 15-year lease with an affiliate of
Alexandria for approximately 244,000 rentable square feet, or 63%, of 75/125
Binney Street, an approximately 386,000 rentable square foot life science
facility, with additional potential expansion opportunities through June 30,
2014. ARIAD's decision to locate its headquarters at 75/125 Binney Street affirms
the Alexandria Center at Kendall Square's reputation as one of the world's most
desirable locations for life science innovation and collaboration.
75/125 Binney Street will facilitate ARIAD's continued discovery, development and
commercialization activities in the oncology field. ARIAD's approximately 20-year
track record of scientific excellence is based on the company's computational
structure-based drug design platform, which has led to several internally
discovered, molecularly targeted product candidates for drug-resistant or
difficult-to-treat cancers. On December 14, 2012, ARIAD announced that the United
States Food and Drug Administration (FDA) approved its drug, Iclusig(TM)
(ponatinib), three months ahead of the action date under the FDA's accelerated
approval program. Iclusig was approved for the treatment of adult patients with
chronic, accelerated, or blast phase chronic myeloid leukemia (CML) that is
resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is
resistant or intolerant to prior TKI therapy.
ARIAD and the U.K. National Cancer Research Institute to Collaborate on SPIRIT 3
Clinical Study
Evaluation of the Impact of Switching CML Patients Treated with a First-line
Tyrosine Kinase Inhibitor to Ponatinib
CAMBRIDGE, Mass. & LONDON, Jan 07, 2013 (BUSINESS WIRE) -- ARIAD Pharmaceuticals,
Inc. (ARIA) and Newcastle University, U.K., on behalf of the U.K. National Cancer
Research Institute (NCRI) CML Working Group, today announced an agreement to
collaborate on a multicenter, randomized Phase 3 trial, named SPIRIT 3, to assess
the impact of switching patients with chronic myeloid leukemia (CML) being
treated with a first-line tyrosine kinase inhibitor, upon suboptimal response or
treatment failure, to ponatinib. The NCRI expects to begin enrollment in the
trial of 1,000 patients at approximately 172 clinical research sites in the U.K.
in the second quarter of 2013.
"The SPIRIT 3 study was designed in partnership with ARIAD to provide the
scientific community and patients living with chronic-phase CML a deeper
understanding of the most effective ways to use TKIs and whether we can improve
treatment outcomes by switching patients to ponatinib, who have failed to achieve
optimal response from imatinib or nilotinib," stated Stephen G. O'Brien,
Professor of Haematology at the Northern Institute for Cancer Research at
Newcastle University, NCRI member and chief investigator of the SPIRIT 3 study.
"We look forward to assessing ponatinib as a treatment in this setting and
evaluating its potential clinical, economic and quality-of-life benefits."
Trial Design and Statistical Analysis
The SPIRIT 3 trial is a randomized, two-arm, multicenter trial that compares
major molecular response (MMR) at three years in newly diagnosed patients treated
with imatinib to those treated with nilotinib, when patients are "rescued" with
ponatinib upon suboptimal response at three or 12 months or treatment failure.
The SPIRIT 3 trial will enroll adult patients with chronic-phase CML diagnosed
within three months and previously untreated for CML with any TKI therapy.
Approximately 1,000 patients will be randomized 1:1 to standard doses of imatinib
(400 mg orally once daily) or nilotinib (300 mg orally twice daily). Patients
will be switched to ponatinib (45 mg orally once daily) based on defined criteria
of suboptimal response, treatment failure, or intolerance to first-line therapy.
The primary endpoint of the study is the proportion of patients who have achieved
MMR at three years on their initially allocated first line of therapy, regardless
of switch to ponatinib. MMR is defined as a less than or equal to 0.1% ratio of
BCR-ABL to ABL transcripts on the International Scale measured in peripheral
blood by PCR testing.
ARIAD and the U.K. National Cancer Research Institute to Collaborate on SPIRIT 3
Clinical Study
Evaluation of the Impact of Switching CML Patients Treated with a First-line
Tyrosine Kinase Inhibitor to Ponatinib
CAMBRIDGE, Mass. & LONDON, Jan 07, 2013 (BUSINESS WIRE) -- ARIAD Pharmaceuticals,
Inc. (ARIA) and Newcastle University, U.K., on behalf of the U.K. National Cancer
Research Institute (NCRI) CML Working Group, today announced an agreement to
collaborate on a multicenter, randomized Phase 3 trial, named SPIRIT 3, to assess
the impact of switching patients with chronic myeloid leukemia (CML) being
treated with a first-line tyrosine kinase inhibitor, upon suboptimal response or
treatment failure, to ponatinib. The NCRI expects to begin enrollment in the
trial of 1,000 patients at approximately 172 clinical research sites in the U.K.
in the second quarter of 2013.
"The SPIRIT 3 study was designed in partnership with ARIAD to provide the
scientific community and patients living with chronic-phase CML a deeper
understanding of the most effective ways to use TKIs and whether we can improve
treatment outcomes by switching patients to ponatinib, who have failed to achieve
optimal response from imatinib or nilotinib," stated Stephen G. O'Brien,
Professor of Haematology at the Northern Institute for Cancer Research at
Newcastle University, NCRI member and chief investigator of the SPIRIT 3 study.
"We look forward to assessing ponatinib as a treatment in this setting and
evaluating its potential clinical, economic and quality-of-life benefits."
Trial Design and Statistical Analysis
The SPIRIT 3 trial is a randomized, two-arm, multicenter trial that compares
major molecular response (MMR) at three years in newly diagnosed patients treated
with imatinib to those treated with nilotinib, when patients are "rescued" with
ponatinib upon suboptimal response at three or 12 months or treatment failure.
The SPIRIT 3 trial will enroll adult patients with chronic-phase CML diagnosed
within three months and previously untreated for CML with any TKI therapy.
Approximately 1,000 patients will be randomized 1:1 to standard doses of imatinib
(400 mg orally once daily) or nilotinib (300 mg orally twice daily). Patients
will be switched to ponatinib (45 mg orally once daily) based on defined criteria
of suboptimal response, treatment failure, or intolerance to first-line therapy.
The primary endpoint of the study is the proportion of patients who have achieved
MMR at three years on their initially allocated first line of therapy, regardless
of switch to ponatinib. MMR is defined as a less than or equal to 0.1% ratio of
BCR-ABL to ABL transcripts on the International Scale measured in peripheral
blood by PCR testing.
want to see what 'Sell on the news looks like"
just watch, couldn't get any funnier, hold on for the ride.....
GL